By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Max-Dohrn-Strasse 8-10

Berlin    10589  Germany
Phone: 49-30-726247-0 Fax: 49-30-726247-225



Drug Discovery

Company News
NOXXON Pharma AG Announces Prospectus Publication And Share Transfer To The Public Offering Compartment Of The Euronext Growth Market 7/12/2017 11:24:11 AM
NOXXON Pharma AG Announces First Patients Treated In Phase I/II Clinical Trial Of Nox-A12 Combined With Keytruda In Metastatic Pancreatic And Colorectal Cancer 7/5/2017 9:16:05 AM
Results Of NOXXON Pharma AG Annual General Meeting 6/29/2017 9:03:06 AM
NOXXON Pharma AG Publishes Annual General Meeting Documents 6/7/2017 11:17:27 AM
NOXXON Pharma AG Announces Collaboration With National Center For Tumor Diseases In Heidelberg For Nox-A12/Keytruda Phase I/II Combination Trial 5/16/2017 1:11:04 PM
NOXXON Pharma AG Reports 2016 Financial Results & Announces Advanced Discussions Regarding A Convertible Bond Financing 5/2/2017 11:45:06 AM
NOXXON Pharma AG Licenses And Assigns Preclinical Spiegelmer Programs To Aptarion 1/4/2017 11:38:08 AM
NOXXON Pharma AG Signs Clinical Immuno-Oncology Collaboration Agreement With Merck & Co. (MRK) To Study Nox-A12 Combined With Keytruda (Pembrolizumab) In Pancreatic And Colorectal Cancer 12/15/2016 10:34:45 AM
NOXXON Pharma AG Releases Its Interim 2016 Results 10/31/2016 9:39:50 AM
NOXXON Pharma AG Demonstrates Synergies Between NOX-A12 And Therapies Working Through T Cells Or NK Cells 10/10/2016 12:17:19 PM